Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Yeast (Saccharomyces cerevisiae) Polyclonal NOB1 Primary Antibody for IP, WB - ABIN2452059
Tone, Tanahashi, Tanaka, Fujimuro, Yokosawa, Toh-e: Nob1p, a new essential protein, associates with the 26S proteasome of growing saccharomyces cerevisiae cells. in Gene 2000
Show all 2 Pubmed References
Human Polyclonal NOB1 Primary Antibody for IHC, IHC (p) - ABIN4340233
Yin, Wang, Jiang, Wang, Wu, Liu: Downregulation of NOB1 inhibits proliferation and promotes apoptosis in human oral squamous cell carcinoma. in Oncology reports 2015
These results suggested that RIOK2 and NOB1 may be potential targets in the treatment of Non-small cell lung cancer (NSCLC), and miR145 may be considered a therapeutic inhibitor of both genes.
our results indicate that miR (show MLXIP Antibodies)-330-5p inhibits non-small-cell lung cancer (NSCLC) cell growth through downregulation of NOB1 expression. Our study suggests that miR (show MLXIP Antibodies)-330-5p may serve as a potential therapeutic target for the treatment of NSCLC
Authors identified that SNHG1 increased human nin one binding protein (NOB1), an oncogene (show RAB1A Antibodies), through sponging miR (show MLXIP Antibodies)-326 as competing endogenous RNA (ceRNA), finally prompting cell growth, migration and invasion in OS.
RIOK2 and NOB1 were highly expressed in NSCLC cells and tissues, and their expression profiles were significantly associated with the Tumour Node Metastasis (TNM (show ODZ1 Antibodies)) clinical stage, lymph node metastasis, and differentiation. RIOK2 expression was correlated with NOB1.
The proto-oncogene (show RAB1A Antibodies) NOB1 as a direct target of miR (show MLXIP Antibodies)-326 in gastric cancer.
The expression of NOB1 was also found to be higher in multidrug-resistant gastric cancer cells than that of sensitive cells. This novel MAb will be valuable for investigating the role of NOB1 in carcinogenesis and multidrug resistance of gastric cancer.
CONCLUSION: Our results suggest that enhanced expression of NOB1 related with poor early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer
NOB1 plays an oncogenic role in laryngeal cancer cells through the regulation of JNK (show MAPK8 Antibodies) signaling pathway.
miR (show MLXIP Antibodies)-139-3p may act as a tumor suppressor that can inhibitcervical cancer cell proliferation, migration and invasion and induce cell apoptosis through down-regulation of NOB1 expression.
we suggest that targeting miR (show MLXIP Antibodies)-192 and NOB1 is a novel strategy which will assist in the development of new therapeutics that will be used in the future to prevent and treat prostate cancer.
In yeast, over 200 protein and RNA cofactors are required for ribosome assembly, and these are generally conserved in eukaryotes. These factors orchestrate modification and cleavage of the initial 35S precursor rRNA transcript into the mature 18S, 5.8S, and 25S rRNAs, folding of the rRNA, and binding of ribosomal proteins and 5S RNA. Nob1 is involved in pre-rRNA processing. In a late cytoplasmic processing step, Nob1 cleaves a 20S rRNA intermediate at cleavage site D to produce the mature 18S rRNA (Lamanna and Karbstein, 2009
NIN1/RPN12 binding protein 1 homolog (S. cerevisiae)
, nin one binding protein
, RNA-binding protein nob1
, RNA-binding protein NOB1
, PSMD8 binding protein 1
, adenocarcinoma antigen recognized by T lymphocytes 4
, phosphorylation regulatory protein HP-10
, protein ART-4
, likely ortholog of mouse nin one binding protein